Tom Van Blarcom, PhD, on Bringing CAR-T Constructs From Oncology to B-Cell Driven Autoimmune Disease
The senior vice president and head of research at Kyverna Therapeutics discussed the company’s investigational CAR-T therapies, KYV-101 and KYV-201.
Tom Van Blarcom, PhD
Advertisement
Articles by Tom Van Blarcom, PhD
Advertisement
Latest Updated Articles
Tom Van Blarcom, PhD, on Bringing CAR-T Constructs From Oncology to B-Cell Driven Autoimmune DiseasePublished: December 1st 2023 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Autologous Stem Cell Therapy for Alzheimer Disease Advances to Phase 2 After Positive Early Findings
2
FDA Approves BMS’s Liso-Cel for R/R Marginal Zone Lymphoma
3
CGTLive®’s Weekly Rewind – December 5, 2025
4
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD
5
